DK2795317T3 - Sammensætning til anvendelse i en fremgangsmåde til kræftudvælgelse - Google Patents

Sammensætning til anvendelse i en fremgangsmåde til kræftudvælgelse Download PDF

Info

Publication number
DK2795317T3
DK2795317T3 DK12806053.0T DK12806053T DK2795317T3 DK 2795317 T3 DK2795317 T3 DK 2795317T3 DK 12806053 T DK12806053 T DK 12806053T DK 2795317 T3 DK2795317 T3 DK 2795317T3
Authority
DK
Denmark
Prior art keywords
met
gly
cancer
cyclic peptide
peptide
Prior art date
Application number
DK12806053.0T
Other languages
English (en)
Inventor
Grethe Tang Dalsgaard
Ian Andrew Wilson
Original Assignee
Ge Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ge Healthcare Ltd filed Critical Ge Healthcare Ltd
Application granted granted Critical
Publication of DK2795317T3 publication Critical patent/DK2795317T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Claims (15)

1. c-Met-bindende cyklisk peptid til anvendelse i en in vivo-afbildningsfremgangsmåde til at assistere i bestemmelsen af hvorvidt en individuel patient tidligere diagnosticeret med kræft, er modtagelig for behandling med anti-Met-terapi, hvilken fremgangsmåde omfatter: (i) at administrere til nævnte individuelle patient et billeddannelsesmiddel, som omfatter 18F-radiomærket c-Met-bindende cyklisk peptid; (ii) billeddannelse mindst et sted af nævnte kræft under anvendelse af positronemissiontomografi (PET) følgende trin (i); (iii) at foretage en bestemmelse fra billeddannelsen af trin (ii) hvorvidt eller ej der er forhøjet optagelse af nævnte billeddannelsesmiddel ved nævnte sted; (iv) når bestemmelsen af trin (iii) viser forhøjet optagelse, da skønnes kræften at overudtrykke c-Met, og anti-Met-terapi bestemmes at være egnet til nævnte patient; (v) når bestemmelsen fra trin (iii) viser ingen forhøjet optagelse, da skønnes kræften ikke at overudtrykke c-Met, og anti-Met-terapi bestemmes ikke at være egnet til nævnte patient; hvor nævnte c-Met-bindende cykliske peptid er et 18 til 30-mer cyklisk peptid af formel I:
(I) hvor: cMBP er af formel II:
(Π) hvor Q er aminosyresekvensen (SEQ-1): -Cysa-X1-Cysc-X2-Gly-Pro-Pro-X3-Phe-Glu-Cysd-Trp-Cysb-Tyr-X4-X5-X6-hvor X1 er Asn, His eller Tyr; X2 er Gly, Ser, Thr eller Asn; X3 er Thr eller Arg; X4 er Ala, Asp, Glu, Gly eller Ser; X5 er Ser eller Thr; X6 er Asp eller Glu; og Cysad er hver cyste in-rester således at rester a og b samt c og d er cykliseret til at danne to separate disulfid-bindinger; A og A' er uafhængigt en hvilken som helst aminosyre anden end Cys, med det forbehold, at mindst en af A og A' er til stede og er Lys; x og y er uafhængigt heltal af værdi 0 til 13, og vælges således at [x + y] = 1 til 13; Z1 er fastgjort til N-terminus af cMBP, og er H eller MIG; Z2 er fastgjort til C-terminus af cMBP og er OH, OBc, eller MIG, hvor Bc er en biokompatibel kation; hver MIG er uafhængigt en stofskiftehæmmende gruppe, hvilken er en biokompatibel gruppe, der hæmmer eller undertrykker in vivo-stofskifte af cMBP-peptidet; hvor cMBP er mærket ved Lys-resten af A- eller A'-grupperne med 18F og hvor anti-Met-terapien fungerer ved direkte inhibering af c-Met-receptoren, ved at interferere med HGF-binding til c-Met eller ved at inhibere c-Met-kinaseaktivitet.
2. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 1, hvor cMBP er af formel IIA:
(ΠΑ) hvor: z er et heltal af værdi 0 til 12, og [x + z] = 0 til 12, og cMBP omfatter kun en Lys-rest.
3. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 1 eller krav 2, hvor Q omfatter aminosyresekvensen af enten SEQ-2 eller SEQ-3: Ser-Cysa-X1-Cysc-X2-Gly-Pro-Pro-X3-Phe-Glu-Cysd-Trp-Cysb-Tyr-X4-X5-X6 (SEQ-2); Ala-Gly-Ser-Cysa-X1-Cysc-X2-Gly-Pro-Pro-X3-Phe-Glu-Cysd-Trp-Cysb-Tyr-X4-X5-X6-Gly-Thr (SEQ-3).
4. Det c-Met-bindende cykliske peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 3, hvor X3 er Arg.
5. Det c-Met-bindende cykliske peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 4, hvor hver af -(A)x- eller -(A')y- -grupperne omfatter et linker-peptid, som vælges fra: - Gly-Gly-Gly-Lys- (SEQ-4), - Gly-Ser-Gly-Lys- (SEQ-5) eller - Gly-Ser-Gly-Ser-Lys- (SEQ-6).
6. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 5, hvor cMBP har aminosyresekvensen (SEQ-7): Ala-Gly-Ser-Cysa-Tyr-Cysc-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cysd-Trp-Cysb- Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys.
7. Det c-Met-bindende cykliske peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 6, hvor både Z1 og Z2 er uafhængigt MIG.
8. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 7, hvor Z1 er acetyl og Z2 er et primært amid.
9. Det c-Met-bindende cykliske peptid til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvori nævnte fremgangsmåde kræften er ikke-småcellet lungekræft, kolorektal kræft, mavekræft, kræft i bugspytkirtlen, kræft i hoved og hals, kræft i æggestokkene, brystkræft, melanom, gliom eller sarkom.
10. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 9, hvori nævnte fremgangsmåde kræften er ikke-småcellet lungekræft, kolorektal kræft eller mavekræft.
11. c-Met-bindende cyklisk peptid til anvendelse ifølge et hvilket som helst af kravene 1-10, hvor, når bestemmelsen af trin (i) er at anti-Met-terapi er egnet til nævnte patient, da påbegyndes eller fortsættes anti-Met-terapi til nævnte patient.
12. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 11, hvor nævnte fremgangsmåde til behandling med anti-Met-terapien omfatter: (a) en ikke-proteinøs c-Met-inhibitor; (b) et anti-Met-antistof; (c) et anti-HGF-antistof eller kombinationer deraf.
13. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 11 eller krav 12, hvori nævnte fremgangsmåde til behandling anti-Met-terapien leveres som en del af en kombinationsterapi med en yderligere behandling, hvor den yderligere behandling vælges fra: (i) en EGFR-inhibitor; (ii) en tyrosinkinaseinhibitor; (iii) en VEGF-inhibitor; (iv) standard kræftkemoterapi; (v) en β-catenininhibitor.
14. c-Met-bindende cyklisk peptid til anvendelse ifølge et hvilket som helst af kravene 11-13, hvor nævnte fremgangsmåde omfatter at udføre henholdsvis billeddannelsen og bestemmelse af trinnene (ii) og (iii) ifølge et hvilket som helst af kravene 1 til 10 ved et eller flere tidsintervaller efter påbegyndelse af nævnte terapi.
15. Det c-Met-bindende cykliske peptid til anvendelse ifølge krav 14, hvor nævnte anti-Met-terapi er som defineret i krav 12 eller krav 13.
DK12806053.0T 2011-12-20 2012-12-19 Sammensætning til anvendelse i en fremgangsmåde til kræftudvælgelse DK2795317T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1121914.4A GB201121914D0 (en) 2011-12-20 2011-12-20 Method for patient selection
PCT/EP2012/076196 WO2013092742A1 (en) 2011-12-20 2012-12-19 Method for patient selection

Publications (1)

Publication Number Publication Date
DK2795317T3 true DK2795317T3 (da) 2018-07-16

Family

ID=45572717

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12806053.0T DK2795317T3 (da) 2011-12-20 2012-12-19 Sammensætning til anvendelse i en fremgangsmåde til kræftudvælgelse

Country Status (10)

Country Link
US (1) US9956303B2 (da)
EP (1) EP2795317B1 (da)
JP (1) JP6186371B2 (da)
KR (1) KR102061366B1 (da)
CN (2) CN103998929A (da)
CA (1) CA2859572C (da)
DK (1) DK2795317T3 (da)
ES (1) ES2676184T3 (da)
GB (1) GB201121914D0 (da)
WO (1) WO2013092742A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
GB201611123D0 (en) * 2016-06-27 2016-08-10 Euremab Srl Anti met antibodiesand uses thereof
IT201800000535A1 (it) 2018-01-03 2019-07-03 Procedimenti per la cura del cancro.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
DK2949658T3 (da) * 2003-03-03 2018-10-01 Dyax Corp Peptider, som specifikt binder HGF-receptor (cMet) og anvendelser deraf
KR20150017387A (ko) 2007-05-16 2015-02-16 지이 헬스케어 에이에스 영상화를 위한 표지된 ｈｇｆ 결합성 펩티드
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method
EP2127683A1 (en) 2008-05-29 2009-12-02 Metheresis Translational Research SA Anti-Met monoclonal antibody, fragments and derivatives thereof for use in tumor imaging, corresponding compositions and kits
EP2454598B1 (en) 2009-07-15 2017-03-22 DiaTech Holdings, Inc. Drug selection for gastric cancer therapy using antibody-based arrays
EP2287197A1 (en) 2009-08-21 2011-02-23 Pierre Fabre Medicament Anti-cMET antibody and its use for the detection and the diagnosis of cancer
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
AU2011226103C1 (en) 2010-03-10 2016-04-28 Genmab A/S Monoclonal antibodies against c-Met
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201121914D0 (en) 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection

Also Published As

Publication number Publication date
CA2859572C (en) 2022-08-02
EP2795317B1 (en) 2018-05-30
KR20140103276A (ko) 2014-08-26
EP2795317A1 (en) 2014-10-29
WO2013092742A1 (en) 2013-06-27
CN109316609A (zh) 2019-02-12
JP2015507620A (ja) 2015-03-12
US9956303B2 (en) 2018-05-01
ES2676184T3 (es) 2018-07-17
CA2859572A1 (en) 2013-06-27
CN103998929A (zh) 2014-08-20
KR102061366B1 (ko) 2019-12-31
US20140335022A1 (en) 2014-11-13
CN109316609B (zh) 2022-03-18
GB201121914D0 (en) 2012-02-01
JP6186371B2 (ja) 2017-08-23

Similar Documents

Publication Publication Date Title
CA2807491C (en) F18 c-met binding cyclic peptide radiotracers and compositions thereof
Perols et al. Influence of DOTA chelator position on biodistribution and targeting properties of 111In-labeled synthetic anti-HER2 affibody molecules
DK2795317T3 (da) Sammensætning til anvendelse i en fremgangsmåde til kræftudvælgelse
BR112015006453B1 (pt) Antagonista de grpr radiomarcado e composição terapêutica que o compreende
US20110117012A1 (en) Radiolabeled gallium complexes, methods for synthesis and use for pet imaging of egfr expression in malignant tumors
WO2011066521A2 (en) Compounds with reduced ring size for use in diagnosing and treating melanoma, including metastatic melanoma and methods related to same
JP2010539112A (ja) 抗腫瘍薬のための分類マーカーとしてのｅｄ‐ｂフィブロネクチン
KR20220034777A (ko) 화합물 및 사용 방법
JP4318985B2 (ja) ソマトスタチンアナログ誘導体およびその利用
EP2695891B1 (en) Octapeptide, radiopharmaceutical agent based thereon and method for diagnosing tumors
Beloborodov ЕА et al. Development and Synthesis of Bombesin-Based Radiopharmaceutical Precursors Modified with Knottin
JP2015083546A (ja) 癌の原発巣・骨転移の検査・治療用放射性標識薬剤